Freeline Hemophilia B Gene Therapy May Have Advantage Over Competitors

Almost No Patients Required Post-Treatment Factor Replacement Therapy

Hemophilia_525478450_1200.jpg
Freeline announced data from the Phase I/II study of its hemophilia B gene therapy. • Source: Shutterstock

More from Blood and Clotting

More from Therapeutic Category